RTTNews | Nov 18, 2021 06:51AM EST

06:50 Thursday, November 18, 2021 (RTTNews.com) - CureVac N.V. (CVAC) published the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK. The data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty. Neutralizing antibody levels measured following full vaccination of animals with either 12g of CV2CoV or a 30g standard dose of Comirnaty were shown to be highly comparable, as per the study.

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected than animals vaccinated with CVnCoV in the study.

Read the original article on RTTNews ( https://www.rttnews.com/3243436/curevac-cv2cov-shows-comparable-antibody-levels-to-licensed-mrna-vaccine-in-preclinical-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved